Excel Treatment Program's Claims Substantiated Again

(PRLEAP.COM) Excel Treatment Program in Denver Colorado has been focused on the treatment of substance addiction through the administration of peptides, amino acids, vitamins, minerals and nutrients for over a decade. Their claims of the importance of the neuro-biological factor in recovery, specifically the dopamine D2 receptor continue to be substantiated. Recently, researchers from the University of Cambridge released a study which once again suggests a direct link between a lack of D2 receptors and a predisposition to drug addiction as well as compulsions such as excessive gambling and shopping.
Tamea Sisco is the discoverer of the transport mechanism for administrating Amino Acid Anti-Craving I.V. treatments, and Program Director of Excel Treatment in Denver, Colorado. She has also discovered that by administering the correct peptides and amino acids, in the correct proportion, to repair this brain cell receptor, addiction cravings are controlled. These brain cell receptors are a subclass of the super family of receptors called G-protein coupled receptors, which are made from amino acids.

"Safety isn’t a problem," comments Sisco, "as each of the individual amino acids are FDA approved. The hard part was finding which amino acids were damaged in the G-receptor and how much to administer." The treatment, termed "Tigers" or "TGGRS" treatment, is administered as a painless intravenous drip over 3-4 hours for a total of 10-20 treatments. National licenses for the TGGRS treatment are currently being offered.

"Tigers" stands for TGGRS which is Third Generation Genetic Repair System and is now patent pending at the US Patent Office.
Contact Information

About This News Release

If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.

Share this News
PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy